Actually, it depends on the agreement. It could be either way.
In Reply to 'seek the light' "We won't be able to use deal funds for anything but B-OM and IBD development, unless the deal comes with strategic investment funds." Not correct at all!!!
Payment for a licensing deal to develop the drug at the buyers expense in a designated area of the world will not put the buyer of the license in control of the upfront money. JMO!!!!